Budget Amount *help |
¥17,160,000 (Direct Cost: ¥13,200,000、Indirect Cost: ¥3,960,000)
Fiscal Year 2021: ¥4,160,000 (Direct Cost: ¥3,200,000、Indirect Cost: ¥960,000)
Fiscal Year 2020: ¥4,160,000 (Direct Cost: ¥3,200,000、Indirect Cost: ¥960,000)
Fiscal Year 2019: ¥4,160,000 (Direct Cost: ¥3,200,000、Indirect Cost: ¥960,000)
Fiscal Year 2018: ¥4,680,000 (Direct Cost: ¥3,600,000、Indirect Cost: ¥1,080,000)
|
Outline of Final Research Achievements |
Messenger RNA cancer vaccines encoding tumor antigens garner much attention in cancer immunotherapy. Immunostimulatory adjuvants play a critical role in cancer vaccines. In the present study, we integrate adjuvant functionalities into mRNA by employing mRNA engineering. The developed mRNA formulation improves vaccination effects in mice after encapsulation into lipid-based mRNA carriers used in clinical trials and polyplex micelles. Ultimately, this system provides therapeutic outcomes in several cancer models.
|